Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FAAH | O00519 | 1/20 | 0.38 |
| ▸ | PARP1 | P09874 | 3/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.34 |
| ▸ | KDM1A | O60341 | 2/20 | 0.34 |
| ▸ | HTR1A | P08908 | 1/20 | 0.34 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.33 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.33 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.33 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.33 |
| ▸ | CSNK1A1 | P48729 | 1/20 | 0.33 |
| ▸ | GRM5 | P41594 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4363957 | 0.83 | P2RY12 (0.41) | MAPK1SIGMAR1 | |
| SCHEMBL30254155 | 0.81 | ALDH1A1 (0.45) | MAPK1GRM5 | |
| SCHEMBL4369710 | 0.79 | CXCR2 (0.37) | FAAHPARP1KDM1AHTR1AHRH4 | |
| SCHEMBL4358423 | 0.78 | FAAH (0.40) | FAAHHRH4 | |
| SCHEMBL29155320 | 0.76 | SIGMAR1 (0.45) | MAPK1SIGMAR1 | |
| SCHEMBL16061780 | 0.74 | FAAH (0.58) | FAAHPARP1MAPK1KDM1A | |
| SCHEMBL28808134 | 0.73 | KDM4E (0.51) | FAAHMAPK1 | |
| SCHEMBL30020659 | 0.73 | NAMPT (0.46) | — | |
| SCHEMBL7383181 | 0.73 | CYP3A4 (0.40) | MAPK1HPGDSIGMAR1 | |
| SCHEMBL27973414 | 0.72 | SMN1; SMN2 (0.41) | PARP1HPGDALOX5SIGMAR1HRH4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090163508-A1 | AMIDE COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-06-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090163508-A1 | AMIDE COMPOUND | FAAH, FAAH2, NAAA | FAAH 1/4885PARP1 3650/4885MAPK1 1901/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.